Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
39 hedge funds and large institutions have $39.6M invested in Eiger BioPharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 17 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
13% less funds holding
Funds holding: 45 → 39 (-6)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
40% less capital invested
Capital invested by funds: $66.2M → $39.6M (-$26.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$384K |
| 2 |
Millennium Management
New York
|
+$350K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$303K |
| 4 |
Goldman Sachs
New York
|
+$261K |
| 5 |
Renaissance Technologies
New York
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.06M |
| 2 |
NC
Nexthera Capital
New York
|
-$3.02M |
| 3 |
BlackRock
New York
|
-$1.19M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.06M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$472K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
STRS Ohio
Columbus,
Ohio
| – | -$13K | -40 | Closed |
|
|
CG
52
Cutler Group
San Francisco,
California
| – | -$12K | -38 | Closed |
|
53
Legal & General Group
London,
United Kingdom
| – | -$10K | -31 | Closed |
|
|
QCG
54
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$4K | -14 | Closed |
|
|
AIP
55
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$3K | -9 | Closed |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -5 | Closed |
|
EIGR Hedge Fund Activity: Q2 2017 in Review
39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2017, worth a combined $39.6M — down 40% from $66.2M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EIGR and 11 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was Hikari Power, adding an estimated $384K. The largest seller was RA Capital Management, exiting entirely with an estimated $4.06M sold.
- 39 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2017, down from 45 in Q1 2017.
- Funds reported $39.6M of Eiger BioPharmaceuticals, Inc. stock for Q2 2017, down 40% quarter-over-quarter.
- 11 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2017 and 17 closed out, a net change of -6 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2017 was Hikari Power, an estimated $384K added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2017 was RA Capital Management, an estimated $4.06M sold.
Based on aggregated 13F filings for Q2 2017.